Hosted on MSN25d
Boral Capital sets $22 target on Scilex shares, rating BuyThe standout in Scilex's pipeline, according to Boral Capital, is SEMDEXA, a clinical-stage dexamethasone gel that has shown positive results in Phase 3 trials for sciatica. The analyst firm views ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback